Condition: Gout Chronic · Gout · DDI (Drug-Drug Interaction) · Sponsor: Atom Therapeutics Co., Ltd
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
This description comes directly from the study's public registry record.
MaoE Sun · 13914017855 · mao.e.sun@atombp.com
Always discuss trial participation with your own doctor first.
| Wakefield Clinical Research | Cary, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07367971